The orphan drug market will reach 176 billion dollars in 2020!

[pharmaceutical network market analysis] in recent years, affected by the pricing advantages of orphan drugs, the industry's R & D enthusiasm for orphan drugs has continued to rise According to an earlier orphan drug research report released by evaluatepharma, there is no sign of slowing down in sales growth in recent years By 2020, orphan drug sales will account for 19% of total prescription drug sales, reaching $176 billion In addition, it is predicted that the annual compound growth rate of the sales scale of drugs identified as orphan drugs by the regulatory authorities of the United States, Europe and Japan will be close to 11% by 2020, while the annual growth rate of drugs for large patient groups will be only about 4% Rare diseases are actually a general term for a very low incidence rate of diseases Also known as orphan diseases, rare diseases are also known as orphan drugs (Orphan Drug) According to the definition of the World Health Organization, diseases with the number of patients accounting for 0.65 ‰ ~ 1 ‰ of the total population can be defined as rare diseases Due to the small scale of clinical practice of rare diseases and the lack of treatment options, it has brought great advantages to the supervision and review of orphan drugs With the high popularity of the global rare disease drug market, more and more orphan drugs are entering the phase II and III clinical research and development stage, and the mature market in many countries makes the number of approved orphan drugs increase significantly It is reported that in 2018, the FDA approved 59 new molecular entities, 34 of which (58%) were used to treat rare diseases Among the orphan drugs approved by FDA, 70% were used to treat tumor diseases, among which 270 were orphans with NHL indications, 220 with AML and 189 with pancreatic cancer In 2018, the number of orphan drugs awarded by FDA to treat Hodgkin's lymphoma, acute myeloid leukemia and pancreatic cancer is still large, indicating that there is still an urgent need for effective medical means for cancer diseases In addition, data show that the global market for drugs for rare diseases in 2018 is US $131 billion, growing rapidly at a compound annual growth rate of 12.3%, and is expected to reach US $242 billion in 2024 The growth rate of rare disease drug market is twice that of non rare disease drug market (6%) in the same period It is estimated that by 2024, its share in the prescription drug market will exceed 20% for the first time At present, under the favorable influence of the global orphan drug market, China has successively introduced relevant measures such as tax reduction, accelerated approval, including orphan drugs in medical insurance, etc., to improve the R & D motivation of domestic pharmaceutical enterprises, so as to protect the rights and interests of patients with rare diseases For example, China's newly promulgated Drug Administration Law in 2019 provides much-needed legal support for ensuring the drug accessibility of patients with rare diseases But on the whole, China still faces many challenges in dealing with rare diseases, including the innovation of new treatment methods, solving the social and economic impact of rare disease patients and families caused by diseases, and ensuring their access to high-quality medical services However, with China's economic growth and adhering to the concept of patient-centered, and constantly promoting the innovation and research and development of new drugs, it will make China's contribution to the global response to orphan drugs with rare diseases and create more value.